Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Breast Cancer Metastatic 1

Interventions

pembrolizumab 18Paclitaxel 13Carboplatin 10Pemetrexed 4Cisplatin 4patritumab deruxtecan 3Gemcitabine 3Docetaxel 3Capecitabine 3Albumin-Bound Paclitaxel 3Histamine H2 Antagonists 2Histamine Antagonists 2Dexamethasone 2Acetaminophen 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1osimertinib 1olaparib 1liposomal doxorubicin 1lenvatinib 1enzalutamide 1cemiplimab 1Vascular Endothelial Growth Factor A 1Serotonin 5-HT3 Receptor Antagonists 1Ramucirumab 1Oxaliplatin 1Neurokinin-1 Receptor Antagonists 1Neoadjuvant Therapy 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × patritumab deruxtecan × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT04165070 2026-05-18

MK-3475-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
450 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡